Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study

HIV Medicine

Volumn 7, Issue 7, 2006, Pages 431-436

  Reliquet, Veronique ^a   Allavena, C ^a   Francois Brunet C ^a   Perre P ^b   Bellein, V ^c   Garre M ^c   May, T ^d   Souala, F ^e   Besnier, J M ^f   Raffi, F ^a  

^a HÔTEL DIEU   (France)

^b Service de Médecine Interne   (France)

^c Service de Médecine Interne   (France)

^d Maladies Infectieuses   (France)

^e Service des Maladies Infectieuses   (France)

^f Service de Médecine Interne A   (France)

Author keywords

Long term efficacy; Nevirapine; Safety

Indexed keywords

ABACAVIR; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LIPOATROPHY; LIVER DYSFUNCTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; OPEN STUDY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33747670862     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00402.x     Document Type: Article

References (21)

1. Gil P, de Gorgolas M, Estrada V et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004; 39: 1024-1029.
2. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
3. Saves M, Chêne G, Ducimetière P et al. for the French Who MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
4. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
5. Shafer RW, Smeaton LM, Robbins GK et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2304-2315.
6. US DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. http://aidsinfo.nih.gov/guidelines/ default_db2.asp?id=50 2004.
7. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2004; 292: 251-265.
8. Raffi F, Reliquet V, Ferre V et al. The VIRGO study: Nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antiviral Ther 2000; 5: 267-272.
9. Van Leeuwen R, Katlama C, Murphy RL et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987-999.
10. Podzamczer D, Ferrer E, Consiglio E et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Ther 2002; 7: 81-90.
11. Gulick RM, Meibohm A, Havlir D et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003; 17: 2345-2349.
12. Eron J, da Silva B, King M et al. Lopinavir/ritonavir (Kaletra) in antiretroviral-naïve HIV+ patients: 5-year follow-up. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 2003 [Poster H-844].
13. Arribas J, Staszewski S, Neslon M et al. Three-year durability of response with an efavirenz-containing regimen: 144-week follow-up from study 006. 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Istanbul, Turkey, April 2001 [Oral Communication]. Available at http://www.akm.ch/eccmid2001.
14. Shalit P, Farrell P, Lindgren P. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting. AIDS 2001; 15: 804-805.
15. Sabin CA, Fischer M, Churchill D et al. Long-term follow-up of antiretroviral-naïve HIV-positive patients treated with nevirapine. J Acquir Immune Defic Syndr 2001; 26: 462-465.
16. Ferrer E, Santamarina E, Domingo P et al. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200cells/microl or less. AIDS 2004; 18: 1727-1729.
17. Gil P, de Gorgolas M, Estrada V et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004; 39: 1024-1029.
18. van Leth F, Phanuphak P, Ruxrungtham K et al. 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
19. Lopez S, Miro O, Martinez E et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004; 9: 47-55.
20. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
21. Pollard R, Hardy D, Peterson D et al. Safety of didanosine plus stavudine combination therapy in HIV-infected subjects in a pilot randomized double-blinded trial. Antiviral Res 1995; 26: A302.